Baxter to proceed with longer-acting Advate
This article was originally published in Scrip
Baxter is progressing with the development of a longer-acting Advate product for the treatment of hemophilia A. The company has filed an IND for BAX 855 with the US FDA following positive Phase I results. Using PEGylation technology through a collaboration with Nektar Therapeutics, the half-life of BAX 855 in the body measured in the Phase I trial was around 1.5-fold higher compared to Advate.